Indegene IPO

Indegene Ltd

₹14,190 /33 sharesMinimum Investment

Indegene IPO Listing Details

Listed OnIssue PriceListing PriceListing Gains
BSE₹452.00₹655.00₹203.00 (44.91%)

Indegene IPO Details

Bidding DatesMin. InvestmentLot SizePrice Range
6 May ‘24 - 8 May ‘24₹14,19033₹430 - ₹452
Issue SizeIPO Doc
1841.76Cr
RHP PDF

Subscription Status As on 08 May '24, 4:00 PM

  • Qualified Institutional Buyers
    139.10x
  • Non-Institutional Investor
    49.79x
  • Retail Individual Investor
    6.94x
  • Employees
    5.42x
  • Total
    52.27x

About Indegene

Indegene Limited provides digital-led commercialization services for the life sciences industry, specifically catering to biopharmaceutical, emerging biotech and medical devices companies. The company assistance in drug development, clinical trials, pharmacovigilance, regulatory submissions, complaints management, and sales/marketing. The company’s solutions enable its client companies to develop and sell products through their life cycle in a more effective, efficient and modern manner. The company offers Enterprise Commercial Solutions and Omnichannel Activation solutions to address the commercial needs of life sciences companies. It also offers Enterprise Medical Solutions and Enterprise Clinical Solutions to support the medical and R&D functions of its client companies.;
Parent Organisation
Indegene Ltd
Founded
1998
Managing Director
Mr. Manish Gupta
https://www.youtube.com/watch?v=kjKRpoxL9OQ

Strengths & Risks

  • As of December 31, 2023, the company had 65 active clients. It provides solutions to these clients from its operation hubs situated across North America, Europe, and Asia.
  • As per the company’s RHP, it maintains long-standing relationships with major biopharmaceutical firms, including each of the 20 largest biopharmaceutical companies globally by revenue for the 2023 financial year.
  • The company meets its clients' needs through six operation hubs and 17 offices spread across North America, Europe, and Asia.
  • As per the company, it has completed several acquisitions since 2005, leveraging the synergies, networks, technologies, and talent pools of the acquired companies to its advantage.
  • The company reported revenue from operations of Rs. 966.27 cr, Rs. 1,664.6 cr and Rs. 2,306.13 cr in FY 2021, 2022 and 2023 respectively. For the same time periods, it reported Profit after tax of Rs. 185.68 cr, Rs. 162.81 cr and Rs. 266.09 cr respectively.
  • Since the company's business is entirely focused on the life sciences industry, and a significant portion of its revenue comes from certain large clients based in North America and Europe, its success and profitability are closely tied to factors impacting the life sciences industry and the ongoing relationships with these key clients.
  • The company relies on sub-contractors and third-party vendors to provide various services, including: (i) quality control services for pharmacovigilance; (ii) payroll services; (iii) software and web development; (iv) quality assurance; (v) medical information support; and (vi) campaign management.
  • The company, along with its subsidiaries and directors, is involved in ongoing legal proceedings. Any adverse outcomes in these proceedings could lead to liabilities or penalties, which might negatively impact the company's business and operating results.
  • The majority of the company’s revenues are derived from its Subsidiaries. Any disruptions in the operations of these Subsidiaries may adversely affect its business, financial condition, results of operations.
  • The company's international operations subject it to a range of challenges, including complex management issues, legal and tax risks, economic uncertainties, and fluctuations in exchange rates. These factors could have a detrimental impact on its business, financial condition, and operating results.

Financials

*All values are in Rs. Cr
No Graph Data To Display

Application details

Apply asPrice bandApply upto
Regular430 - 452₹2 Lakh
Employee400 - 422₹2 Lakh
High Networth Individual430 - 452₹2 - 5 Lakh
For Indegene IPO, eligible investors can apply as Regular & Employee.
ⓒ 2016-2024 Groww. All rights reserved, Built with in India
MOST POPULAR ON GROWWVERSION - 5.0.0
STOCK MARKET INDICES:  S&P BSE SENSEX |  S&P BSE 100 |  NIFTY 100 |  NIFTY 50 |  NIFTY MIDCAP 100 |  NIFTY BANK |  NIFTY NEXT 50
MUTUAL FUNDS COMPANIES:  GROWWMF |  SBI |  AXIS |  HDFC |  UTI |  NIPPON INDIA |  ICICI PRUDENTIAL |  TATA |  KOTAK |  DSP |  CANARA ROBECO |  SUNDARAM |  MIRAE ASSET |  IDFC |  FRANKLIN TEMPLETON |  PPFAS |  MOTILAL OSWAL |  INVESCO |  EDELWEISS |  ADITYA BIRLA SUN LIFE |  LIC |  HSBC |  NAVI |  QUANTUM |  UNION |  ITI |  MAHINDRA MANULIFE |  360 ONE |  BOI |  TAURUS |  JM FINANCIAL |  PGIM |  SHRIRAM |  BARODA BNP PARIBAS |  QUANT |  WHITEOAK CAPITAL |  TRUST |  SAMCO |  NJ

ABOUT GROWW